<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444860</url>
  </required_header>
  <id_info>
    <org_study_id>V211-019</org_study_id>
    <secondary_id>MKV211-019</secondary_id>
    <secondary_id>2007_008</secondary_id>
    <nct_id>NCT00444860</nct_id>
  </id_info>
  <brief_title>ZOSTAVAX(R) Local Registration Trial (V211-019)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(R) in Healthy Adults in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain safety and immunogenicity data for the
      refrigerator-stable formulation of ZOSTAVAX(R) in taiwanese adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The geometric mean fold rise (GMFR) of subjects VZV antibody titers from prevaccination to 4 weeks postvaccination, and the geometric mean titers (GMTs) at prevaccination and 4 weeks postvaccination, as measured by gpELISA, will be assessed.</measure>
    <time_frame>prevaccination and 4 weeks postvaccination</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Varicella Virus Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zostavax</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zoster Vaccine, Live, (Oka-Merck)</intervention_name>
    <description>A single dose of 0.65 ml of Zostavax injection was given to each study subject</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zostavax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject Is Older Than 50 Years Of Age On Day Of Signing Informed Consent

          -  All Females Must Be Postmenopausal Or Have A Negative Serum Or Urine Pregnancy Test

               -  Postmenopausal Is Defined As 6 Months Of Spontaneous Amenorrhea With Serum
                  Follicle Stimulating Hormone (Fsh) Levels In The Postmenopausal Range As
                  Determined By The Laboratory, Or 12 Months Of Spontaneous Amenorrhea

          -  A Subject Who Is Of Reproductive Potential Must Agree To Remain Abstinent Or Use (Or
             Have Her Partner Use) 2 Acceptable Methods Of Birth Control For Three Months After
             Vaccination

               -  Acceptable Methods Of Birth Control Are: Intrauterine Device, Diaphragm With
                  Spermicide, Contraceptive Sponge, Oral Contraceptive Pills, Condom, Tubal
                  Ligation, And Vasectomy

          -  Subject Must Sign Informed Consent Prior To Any Study Procedure

          -  Subject Must Be afebrile (&lt;38.3 Â°C Oral) On Day Of Vaccination

          -  Any Underlying Chronic Illness Must Be In Stable Condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <results_reference>
    <citation>Yao CA, Chen LK, Huang KC. The immunogenicity and safety of zoster vaccine in Taiwanese adults. Vaccine. 2015 Mar 24;33(13):1515-7. doi: 10.1016/j.vaccine.2015.01.085. Epub 2015 Feb 11.</citation>
    <PMID>25681662</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

